FilipaLynceMD

PubMed

• Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.
  Julieta Leone, Carlos T Vallejo, Olga Martínez-Sáez, Nabihah Tayob, Paolo Tarantino, Rachel A Freedman, Adrienne G Waks, Ana Garrido-Castro, Filipa Lynce, Nancy U Lin,...> ;NPJ Breast Cancer. 2024 Apr 4
• Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
  Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan, Eren Yeh, Laura Warren, Jennifer Bellon, Beth Harrison, Toshiaki Iwase, H T Carisa Le-Petross,...> ;Breast Cancer Research and Treatment. 2024 Apr 1
• Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
  Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Nature Communications. 2024 Mar 27
• PARP Inhibitors for Breast Cancer Treatment: A Review.
  Stefania Morganti, Antonio Marra, Carmine De Angelis, Angela Toss, Luca Licata, Federica Giugliano, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Ang...> ;JAMA Oncology. 2024 Mar 21
• A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
  Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai, Qianjun Chen, Yawei Shi, Huijuan Sh...> ;Cancer Research. 2024 Mar 20
• Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
  Ilana Schlam, Joshua Dower, Filipa Lynce> ;Current Oncology Reports. 2024 Apr 1
• TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
  Filipa Lynce, Laura E Stevens, Zheqi Li, Jane E Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M Force, Tufia C Haddad, Naoto Ueno, Vered Stea...> ;Breast Cancer Research. 2024 Jan 31
• From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
  Filipa Lynce, Nancy U Lin> ;Clinical Cancer Research. 2024 Apr 1
• Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
  Bedrosian, I., Somerfield, M., Achatz, M., Boughey, J., Curigliano, G., Friedman, S., Kohlmann, W., Kurian, A., Laronga, C., Lynce, F., Norquist, B., Plichta, J., Rodr...> ;Journal of Clinical Oncology. 2024 Feb 10
• Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
  Song, F., Tarantino, P., Garrido-Castro, A., Lynce, F., Tolaney, S., Schlam, I.> ;Current Oncology Reports. 2024 Jan 1
• Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
  Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Medrxiv. 2023 Dec 4
• Preoperative Risk Factors for Lymphedema in Inflammatory Breast Cancer.
  Libby R Copeland-Halperin, Colby J Hyland, Goutam K Gadiraju, David H Xiang, Jennifer R Bellon, Filipa Lynce, Tanujit Dey, Elizabeth P Troll, Sean J Ryan, Faina Nakhli...> ;Journal of Reconstructive Microsurgery. 2024 May 1
• Endometrial Cancer Risk Among Germline/Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps.
  Kimia Sorouri, Filipa Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, ...> ;JCO Precision Oncology. 2023 Sep 1
• Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
  Ana C Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E Warren, Jennifer R Bellon, Eren ...> ;NPJ Breast Cancer. 2023 Jun 2
• 2 citations
  A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refract...
  Tina Roy, Elizabeth Barrows, Candace Mainor, Julie Collins, Filipa Lynce, Claudine Isaacs, Paula R Pohlmann> ;Contemporary Clinical Trials Communications. 2023 Jun 1
• 2 citations
  Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
  Stefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, Ana C Garrido-Castro, Anna Weiss, Caroline C Block, Ann H Partridge, Giuseppe Curigliano, Nadine M Tung, Nan...> ;The Oncologist. 2023 Jul 5
• 3 citations
  Tailoring Treatment for Patients with Inflammatory Breast Cancer.
  Alexandra B Newman, Filipa Lynce> ;Current Treatment Options in Oncology. 2023 Jun 1
• Copy Number Variation in Inflammatory Breast Cancer.
  Aditi Hazra, Andrea O'Hara, Kornelia Polyak, Faina Nakhlis, Beth T Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce> ;Cells. 2023 Apr 4
• Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
  Hai P Nguyen, Rory Sheng, Elizabeth Murray, Yusuke Ito, Michael Bruck, Cassidy Biellak, Kelly An, Filipa Lynce, Deborah A Dillon, Mark Jesus M Magbanua, Laura A Hupper...> ;Biorxiv. 2023 Mar 29
• Cultural adaptations to a telephone genetic counseling protocol and booklet for Latina breast cancer survivors at risk for hereditary breast and ovarian cancer.
  Sara Gómez-Trillos, Kristi D Graves, Katie Fiallos, Marc D Schwartz, Beth N Peshkin, Heidi Hamilton, Vanessa B Sheppard, Susan T Vadaparampil, Claudia Campos, Ana Paul...> ;Translational Behavioral Medicine. 2023 May 13
• Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer.
  Filipa Lynce, Mark Robson> ;Cancer Treatment and Research. 2023 Jan 1
• 3 citations
  HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving...
  Paula R Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa Lynce, Robert Warren, Asma Dilawari, Suman Rao, Ca...> ;Breast Cancer Research and Treatment. 2022 Dec 1
• 4 citations
  Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
  Laura E G Warren, Samuel M Niman, Marie C Remolano, Jean M Landry, Faina Nakhlis, Jennifer R Bellon, Ayal A Aizer, Nancy U Lin, Sara M Tolaney, Meredith M Regan, Beth ...> ;Cancer. 2022 Dec 1
• 5 citations
  Emerging Targeted Therapies for Early Breast Cancer.
  Ilana Schlam, Stefania Morganti, Filipa Lynce, Dario Trapani, Erica L Mayer, Ana C Garrido-Castro, Ada Waks, Sara M Tolaney, Tarantino, P.> ;Drugs. 2022 Sep 1
• 3 citations
  Molecular characterization of ESR1 variants in breast cancer.
  Arielle L Heeke, Andrew Elliott, Rebecca Feldman, Hazel F O'Connor, Paula R Pohlmann, Filipa Lynce, Sandra M Swain, Maria R Nunes, Daniel Magee, Matthew J Oberley, Jef...> ;Breast Cancer Research and Treatment. 2022 Nov 1
• Join now to see all

Journal Articles

• Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer  
  Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Lectures

• SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018